Eden Review: One Checkout Where the Evidence Runs From Phase 3 to Nothing At All

The same table, two kinds of evidence

Eden's GLP-1 pricing block has six rows. Compounded semaglutide, $99 a month. Compounded tirzepatide, $199. Ozempic, $1,399. Zepbound, $1,399. Mounjaro, $1,399. Wegovy, $1,695. The heading above them reads "Medication made affordable. Without the need for insurance."

Nothing in that table is false. Directly beneath it sits a disclaimer most competitors bury: "Compounded medications may be prescribed by physicians but have not been FDA regulated for safety, effectiveness, or quality. FDA-approved medicines containing semaglutide are available." That is accurate, it is prominent, and Eden deserves credit for its placement.

The problem is arrangement rather than wording. A table sorted by price, under a heading about affordability, tells the reader that these are the same thing at different prices. They are not. Wegovy rests on STEP 1 — 1,961 adults randomised to once-weekly semaglutide 2.4 mg or placebo for 68 weeks, published in the New England Journal of Medicine. ^{1 2} Zepbound rests on SURMOUNT-1, 2,539 adults over 72 weeks. ³ Eden's compounded semaglutide rests on the argument that it contains the same molecule. No compounded semaglutide preparation has been through a registered trial — not Eden's, not anyone's — and FDA does not review compounded preparations for safety, effectiveness or quality, which is precisely what the disclaimer says.

Whether that gap matters is a judgement, and it is yours to make. But it is a different judgement from the one the table invites, which is about money.

Sermorelin, and what "science-based" is standing in for

The sermorelin page is where this site's method earns its keep, because the copy is careful enough to survive a lawyer and not careful enough to survive the literature.

Here is the load-bearing sentence, verbatim: "Sermorelin acts on the pituitary gland to encourage the release of growth hormone, which may help support lean body mass, healthy recovery, and restful sleep as part of a healthy lifestyle. By stimulating natural hormone pathways, Sermorelin offers a balanced, science-based approach to supporting metabolic function and vitality."

The first clause is true. Sermorelin is a growth-hormone-releasing hormone analogue — the 1-29 fragment — and it does stimulate pituitary GH release. That is why it existed: it was approved as Geref and used largely as a diagnostic agent to test whether a pituitary could respond, before being discontinued.

Everything after the first clause is where the sentence leaves the evidence behind. As of August 2026, a PubMed search for sermorelin filtered to the randomised-controlled-trial publication type returns 19 records. The newest is from 2005. ⁴ Reading the list is instructive: they are studies of GH response to a challenge, of growth in children with GH deficiency, of the interaction between clonidine and GHRH, of low-dose bolus dose-response. Not one measures lean body mass, recovery, or sleep quality in healthy adults, because that is not what anybody was studying.

ClinicalTrials.gov tells the same story from the other end. A search for sermorelin as an intervention returns 27 studies. The two closest to Eden's marketed use are NCT01410799, a three-month GHRH study in the elderly, and NCT00807365, its six-month counterpart. Both are phase 2. Both are TERMINATED. Their enrolments were 13 and 5.

So: "science-based" describes a real pharmacological mechanism and an evidence base that has never been pointed at the outcomes being sold. "May help support" is doing the legal work; "science-based" is doing the persuasive work; and the two are pulling in opposite directions. If you want the full picture on what growth-hormone-axis peptides have and have not been shown to do, that is a compound question rather than a provider one — start with the evidence pages rather than a product page.

The one product Eden describes perfectly

Two clicks away, Eden does the opposite, and it is worth dwelling on because it proves the company can.

Its safety page says of the GHK-Cu foam: "GHK-Cu 0.5% Foam is a compounded prescription therapy prepared by licensed 503A compounding pharmacies. This product is considered an experimental wellness therapy intended to support scalp health and general tissue vitality. It is not FDA-approved for the treatment, prevention, or cure of any medical condition, including hair loss disorders such as androgenetic alopecia."

Read that again with a marketer's eye. It names the regulatory category correctly. It calls the company's own product experimental. And it goes out of its way to name androgenetic alopecia — the exact thing a person buying a hair foam is hoping for — as something the product is not approved to treat. The product page title matches: "Cosmetic Scalp Support & Hair Appearance," not a regrowth claim.

That description survives the literature comfortably, which is the test. As of August 2026 ClinicalTrials.gov lists three studies with GHK-Cu as an intervention: one completed 27-participant phase 4 study of facial skin quality and barrier function, one recruiting phase 2 wound-healing study, and one not yet recruiting. ⁵ None concerns hair. Eden's word for that state of affairs is "experimental," and it is the right word.

Which raises the obvious question. The phrase "Regulatory Status" appears exactly twice on Eden's safety page — for GHK-Cu and for minoxidil. Sermorelin, NAD+, glutathione and methylene blue each get a side-effect list and no statement of what they are or are not approved for. The company knows how to write this paragraph. It has written it twice.

Who fills your vial, and what the FDA letter actually said

On June 8, 2026, FDA wrote to Eden Health International Inc. after reviewing tryeden.com in March. Two allegations, both misbranding under sections 502(a) and 502(bb), both about labelling and advertising. There is no allegation about sterility, potency or contamination anywhere in the letter.

The first: the compounded semaglutide and tirzepatide products pictured on the site "identify 'Eden' on the pictured label, suggesting Eden is the compounder of those drugs when in fact it is not." The second: the site described its supply as coming from "FDA-licensed 503(a) outsourcing facilities," to which FDA responded that "[c]ompounding facilities, including pharmacies and outsourcing facilities, are not 'FDA-approved' or 'FDA-licensed' entities. The FD&C Act does not establish an 'FDA-approved' or 'FDA-licensed' designation for pharmacies or outsourcing facilities." ⁷ That sentence — which also, incidentally, condemns a banner running today on the manufacturer-owned pharmacy reviewed elsewhere on this site — is one of the most useful things FDA has published for consumers in this category.

A warning letter is a public regulatory communication. It is not a finding of illegal activity, it is not a shutdown, and firms routinely respond with corrective action. So the question worth asking is what has changed, and the answer is: one of the two things, verifiably.

Searching Eden's home page, GLP-1 treatments page, sermorelin page, Zepbound page and safety-information page on August 7, 2026, the phrase "FDA-licensed 503(a) outsourcing facilities" does not appear anywhere. The safety page instead reads "prepared by licensed 503A compounding pharmacies," which is correct. That is a real fix, and reporting the letter without reporting the fix would be publishing a snapshot as though it were a state.

The first allegation has become more complicated rather than resolved. Eden now runs a compounding pharmacy under its own brand: edenpharmacy.com, whose banner reads "Contigo is now Eden Pharmacy!", operating from 8300 Carmel Ave, Suite 601, Albuquerque, New Mexico, and licensed in 30 states plus the District of Columbia. FDA's premise — that Eden is not the compounder — may no longer hold for every prescription. What has not changed is the thing a customer actually needs: no Eden product page names which pharmacy made the vial in front of them. The strongest statement anywhere on the site is "[o]ur medication is delivered from a state licensed pharmacy in our network."

What the testing page says, and the one number in it that matters

Eden publishes more about quality control than most of this market, and the detail is what makes it useful.

Four tests are named. Sterility: "[e]very batch is tested and must meet the requirements of USP 797." Endotoxins: "[e]very batch is tested for bacterial endotoxins, which may not exceed the threshold limits defined in USP 85." pH: an acid-base check to limit injection-site irritation. And potency: "[t]his test is performed every 3 to 6 months. It confirms that the medication has plus or minus 10% of the appropriate concentration of the active ingredient."

Three of the four run per batch. The one that establishes how much drug is actually in your vial runs two to four times a year.

Eden states this plainly, and stating it plainly is genuinely better than the alternative — most competitors write "third-party tested" and let you assume. But the asymmetry is the finding. Contamination testing protects against something catastrophic and rare. Potency testing protects against the ordinary, likely failure mode of compounding: a vial that is not the strength it says it is. On a $99 compounded semaglutide with no NDC, no approval and no published certificate of analysis, potency is the number you have least other means of checking.

The laboratories are described as "FDA and DEA registered" and are not named. No certificate of analysis is published for any lot.

The membership, which is the second bill

One structural point that has nothing to do with evidence and everything to do with the number you will actually pay. Every price on Eden is medication only. The footnote: "An active Eden Membership is required ($39 for the first month, auto-renews at $99/month thereafter). Membership does not include or guarantee a prescription. Medication is not available without a membership."

So compounded semaglutide advertised at $99 is $138 in month one and $198 a month from month two — the membership having more than doubled in the interval. Sermorelin advertised "from $126 first month" is $165 in month one and $225 a month afterwards, assuming the medication price itself does not also step up from its first-month rate, which the wording "from $126 first month" leaves open and the site does not resolve.

Both halves are published. Neither is hidden. But the number in the large type is never the number on the card.